For the first time, the FDA approves a cancer drug for use based on biomarker and not origin
Pembrolizumab is the first drug approved by the U.S. Food and Drug Administration for use based on a biomarker (a specific genetic feature) rather than the location in the body where the tumor originated. The drug is indicated [more]